Breaking News Instant updates and real-time market news.

FB

Facebook

$143.68

-0.12 (-0.08%)

, VZ

Verizon

$47.25

-1.16 (-2.40%)

16:30
04/21/17
04/21
16:30
04/21/17
16:30

On The Fly: Stocks end week higher as earnings bolster market

Stocks ended the week higher as a steady stream of earnings continued to bolster market sentiment and as investors await results from the French presidential election this upcoming Sunday. MACRO NEWS: In the U.S., the Empire State manufacturing index dropped to 5.2 in April. The NAHB homebuilder sentiment index fell 3 points to 68 in April. Housing starts dropped 6.8% to a 1.215M rate in March. Industrial production rose 0.5% in March. Initial jobless claims rose 10,000 to 244,000 in the week ended April 15. The Philly Fed manufacturing index fell 10.8 points to 22.0 in April. The U.S. leading index rose 0.4% to 126.7 in March. Markit's manufacturing PMI dipped 0.5 points to 52.8 in the April flash reading. Existing home sales rebounded 4.4% to a 5.71M rate in March... In Fed news, the Federal Reserve said in its Beige Book that economic activity increased in each of the twelve Fed districts between mid-February and the end of March, with the pace of expansion equally split between modest and moderate. The Fed added that labor markets "remained tight" during this period and employers in most districts had "more difficulty filling low-skilled positions, although labor demand was stronger for higher skilled workers"... In Europe, U.K. Prime Minister Theresa May called a snap general election to be held on June 8. April's Eurozone consumer confidence flash beat expectations, coming in at -3.6 points. Markit's flash Eurozone PMI manufacturing index for April strengthened to 56.8... In Asia, China's economy grew 6.9% in the first quarter from a year earlier. China's GDP in January-March rose 1.3% quarter on quarter from the previous three months. March industrial production grew 7.6% and retail sales rose 10.9%. Japan's Ministry of Finance reported a merchandise trade surplus for March. Exports rose at an annualized 12% in March, while imports rose 15.8%. Japan's manufacturing PMI rose to 52.8 in April on a seasonally adjusted basis... Additionally, the IMF boosted its 2017 estimate for global economic growth to 3.5% from 3.4%, attributing the upward revision to "buoyant" financial markets and a long awaited cyclical recovery in manufacturing and trade. COMPANY NEWS: On Tuesday, Facebook (FB) shares were in focus after it featured many of its upcoming augmented reality capabilities and premiered the next version of its Messenger app at its F8 conference. However, the event was marred by news that Steve Stephens, the man who on Sunday morning posted a video of himself shooting and killing an elderly man, committed suicide after being confronted by police in Pennsylvania... Arconic (ARNC) announced that Klaus Kleinfeld has stepped down as Chair and CEO and has resigned as a Board member. This comes after the Board learned that Kleinfeld had sent a letter directly to a senior officer of Elliott Management that the board determined "showed poor judgment." In response, Elliott said that the letter "read as a threat" to intimidate or extort a senior officer of Elliott based on "completely false insinuations"... 21st Century Fox (FOX) confirmed that Bill O'Reilly will not return to Fox News "after a thorough and careful review" of the allegations surrounding the longtime host of "The O'Reilly Factor"... The Food and Drug Administration rejected Incyte (INCY) and mega-cap partner Eli Lilly's (LLY) application for rheumatoid arthritis therapy baricitinib in its current form, due to safety concerns... In M&A news, Straight Path Communications (STRP) said that an unnamed party, later named by Reuters as Verizon (VZ), could look to beat AT&T's (T) takeover offer for the company. Alere (ALR) and Abbott (ABT) announced an amended merger deal that will see Abbott pay $51 per share to acquire the diagnostics specialist, putting an end to their fight over the prior terms of their merger agreement. Alibaba's (BABA) affiliate Ant Financial Services Group raised its offer to acquire Moneygram International (MGI) to $18 per share in cash. Cabela's (CAB) announced a deal under which Synovus Bank (SNV) would acquire certain assets and assume certain liabilities of Cabela's unit World's Foremost Bank. Cardinal Health (CAH) announced that it will acquire a patient product portfolio from Medtronic (MDT) for $6.1B. Virtu Financial (VIRT) announced that it has entered into a definitive agreement to acquire KCG Holdings (KCG) for $20.00 per share, or approximately $1.4B equity value... Among companies that announced quarterly results this week, American Express (AXP), Qualcomm (QCOM), CSX (CSX), Honeywell (HON), Visa (V), GNC Holdings (GNC), Morgan Stanley (MS), Intuitive Surgical (ISRG), Hawaiian Holdings (HA), Rockwell Collins (COL), and Proofpoint (PFPT) advanced following their reports, while IBM (IBM), Verizon, Travelers (TRV), Goldman Sachs (GS), Bank of America (BAC), Johnson & Johnson (JNJ), Netflix (NFLX), Barracuda Networks (CUDA), Interactive Brokers (IBKR), eBay (EBAY), Philip Morris (PM), General Electric (GE), and Mattel (MAT) declined. INDEXES: For the week, the Dow rose 0.48% to 20,547.76, the Nasdaq advanced 1.8% to 5,910.52, and the S&P 500 gained 0.88% to 2,348.69.

FB

Facebook

$143.68

-0.12 (-0.08%)

VZ

Verizon

$47.25

-1.16 (-2.40%)

LLY

Eli Lilly

$81.89

-0.05 (-0.06%)

ARNC

Arconic

$26.00

-0.11 (-0.42%)

FOX

21st Century Fox

$30.22

-0.33 (-1.08%)

FOXA

21st Century Fox

$30.70

-0.37 (-1.19%)

STRP

Straight Path

$109.59

0.43 (0.39%)

T

AT&T

$39.93

-0.43 (-1.07%)

ALR

Alere

ABT

Abbott

$43.53

-0.45 (-1.02%)

BABA

Alibaba

$113.11

0.15 (0.13%)

MGI

MoneyGram

$17.79

0.12 (0.68%)

CAB

Cabela's

$56.94

-0.11 (-0.19%)

SNV

Synovus

$41.89

-0.22 (-0.52%)

CAH

Cardinal Health

$72.50

-0.81 (-1.10%)

MDT

Medtronic

$80.48

-0.54 (-0.67%)

VIRT

Virtu Financial

$16.05

-0.4 (-2.43%)

KCG

KCG Holdings

GNC

GNC Holdings

$8.24

-0.54 (-6.15%)

MS

Morgan Stanley

$41.80

-0.7 (-1.65%)

ISRG

Intuitive Surgical

$813.43

-1.02 (-0.13%)

AXP

American Express

$79.59

-0.43 (-0.54%)

QCOM

Qualcomm

$52.50

-0.16 (-0.30%)

CSX

CSX

$50.77

1.21 (2.44%)

HON

Honeywell

$127.08

3.31 (2.67%)

V

Visa

HA

Hawaiian Holdings

$53.25

1.35 (2.60%)

COL

Rockwell Collins

$104.70

5.11 (5.13%)

PFPT

Proofpoint

$77.65

6.65 (9.37%)

GS

Goldman Sachs

$216.86

-1.2 (-0.55%)

BAC

Bank of America

$22.71

-0.36 (-1.56%)

JNJ

Johnson & Johnson

$121.76

-0.11 (-0.09%)

NFLX

Netflix

$142.87

1.69 (1.20%)

CUDA

Barracuda

$20.14

0.66 (3.39%)

IBM

IBM

$160.38

-1.92 (-1.18%)

IBKR

Interactive Brokers

$34.03

-0.3 (-0.87%)

TRV

Travelers

$119.10

0.22 (0.19%)

EBAY

eBay

$32.18

-0.35 (-1.08%)

PM

Philip Morris

$109.62

-0.36 (-0.33%)

GE

General Electric

$29.55

-0.72 (-2.38%)

MAT

Mattel

$21.79

-3.42 (-13.57%)

INCY

Incyte

$123.01

-0.1 (-0.08%)

  • 21

    Apr

  • 21

    Apr

  • 21

    Apr

  • 22

    Apr

  • 22

    Apr

  • 24

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 26

    Apr

  • 26

    Apr

  • 27

    Apr

  • 28

    Apr

  • 01

    May

  • 01

    May

  • 03

    May

  • 03

    May

  • 04

    May

  • 04

    May

  • 07

    May

  • 09

    May

  • 09

    May

  • 09

    May

  • 09

    May

  • 10

    May

  • 10

    May

  • 10

    May

  • 16

    May

  • 17

    May

  • 18

    May

  • 22

    May

  • 23

    May

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 06

    Jun

  • 15

    Jun

  • 22

    Jun

  • 22

    Jun

  • 18

    Jul

  • 17

    Oct

FB Facebook
$143.68

-0.12 (-0.08%)

04/17/17
AGIS
04/17/17
NO CHANGE
Target $160
AGIS
Buy
Facebook price target raised to $160 ahead of F8, earnings at Aegis
Aegis analyst Victor Anthony said he expects Facebook's annual "F8" developer conference this week and the company's Q1 earnings report on May 3 to both be catalysts for the stock and raised his price target on the shares to $160 from $155 ahead of the events. He expects F8 to focus on innovations with the camera and video and he predicts the company will report solid quarterly results given strong advertiser checks. Anthony keeps a Buy rating on Facebook shares.
04/19/17
MSCN
04/19/17
NO CHANGE
MSCN
Facebook overall trends remain 'very strong,' says MScience
MScience analyst Steven Weinstein is forecasting Facebook's North American revenues of 4.07B, down slightly from $4.08B, above consensus of $4.005B. The analyst said slowing increases in US spending per advertiser led to a modest deceleration in revenue growth, but these trends are reflected in management's comments regarding ad load leveling off. Weinstein views overall trends as "very strong."
04/17/17
FBCO
04/17/17
NO CHANGE
Target $175
FBCO
Outperform
Facebook price target raised to $175 from $170 at Credit Suisse
Credit Suisse analyst Stephen Ju raised his price target for Facebook to $175 from $170 ahead of Q1 results, and as he increases his ad volume growth estimates for 2H17 from what he felt was "an excessively conservative" level, offset by higher anticipated content spend. The analyst reiterates an Outperform rating on the shares.
04/21/17
MKMP
04/21/17
NO CHANGE
MKMP
Facebook Q1 results likely to beat expectations, says MKM Partners
MKM Partners analyst Rob Sanderson expects Facebook's Q1 results to beat expectations, and he believes that the company's "tone" on the the likely deceleration of ad load growth in 2H17 has "softened." He adds that user growth and engagement will continue to be an area of focus, given "greater focus" on competition from Snapchat (SNAP). However, he continues to believe that Facebook is "a core holding for growth investors" and keeps a Buy rating.
VZ Verizon
$47.25

-1.16 (-2.40%)

04/20/17
BTIG
04/20/17
NO CHANGE
BTIG
Comcast should try 'hail mary' Charter acquisition, says BTIG
BTIG analyst Rich Greenfield makes the case that Comcast's (CMCSA) "window for M&A is simply to enticing too ignore" and lays out six potential targets that would "truly be transformative," with his top pick among the group being Charter (CHTR). A combination of Charter with Comcast would have "all of the benefits of the legacy Time Warner Cable deal with even more scale" and even though odds of approval are no better than 50/50, it is worth throwing that "hail-mary," Greenfield tells investors. The other five possible deals that Greenfield makes the case for are Disney (DIS), Verizon (VZ), Netflix (NFLX), T-Mobile (TMUS) and Snap Inc.'s (SNAP) Snapchat.
04/21/17
04/21/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Verizon (VZ) downgraded to Hold from Buy at Argus with analyst Joseph Bonner citing the company's subscriber losses and "intense competition." He says that the company has been forced to offer "unsubsidized phone plans and unlimited data" which have hurt its results. 2. Cabot Oil & Gas (COG) downgraded to Outperform from Strong Buy at Raymond Jame with analyst John Freeman citing recent outperformance and lower natural gas pricing forecasts. 3. Manhattan Associates (MANH) downgraded to Hold from Buy at Benchmark with analyst Mark Schappel noting that the company's cut to its 2017 revenue outlook was its third consecutive guide down. Schappel lowered his price target on Manhattan Associates shares to $48 from $65. 4. Humana (HUM) downgraded to Hold from Buy at Jefferies with analyst David Windley saying he views the as expensive and points out that 2018 premium growth under President Trump is lower than 2017 under Obama. 5. Plains All American (PAA) downgraded to Hold from Buy at Jefferies with analyst Christopher Sighinolf saying the valuation appears full at current share levels. The analyst lowered his price target for the name to $27 from $28. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/21/17
ARGS
04/21/17
DOWNGRADE
ARGS
Hold
Verizon downgraded to Hold from Buy at Argus
Argus analyst Joseph Bonner,downgraded Verizon based on the company's subscriber losses and "intense competition." He says that the company has been forced to offer "unsubsidized phone plans and unlimited data" which have hurt its results.
04/21/17
OPCO
04/21/17
NO CHANGE
OPCO
Perform
Verizon responding to wireless competition, says Oppenheimer
Oppenheimer analyst Timothy Horan expects Verizon's (VZ) equipment revenue in Q4 to be strong, linked to the release of the new iconic Apple (AAPL) iPhone 8. The analyst believes wireless competition will remain elevated, but Verizon is responding, and will remained focused on network quality. Further, Horan says Verizon is integrating Yahoo (YHOO)/AOL to deliver growth from programmatic ads/digital content, but this will take some time. He reiterates a Perform rating on Verizon's shares.
LLY Eli Lilly
$81.89

-0.05 (-0.06%)

04/17/17
COWN
04/17/17
NO CHANGE
Target $95
COWN
Outperform
Eli Lilly price target raised to $95 at Cowen despite Olumiant 'disappointment'
Cowen analyst Steve Scala admitted that the CRL for baricitinib is a "significant disappointment" for Eli Lilly, while noting he has always leaned conservatively on the drug and that his Olumiant forecasts are "roughly intact" as he assumes a U.S. launch in January 2019. However, Scala raised his price target on Eli Lilly to $95 from $85 despite the Olumiant disappointment based on a number of upcoming new product rollouts and late stage agents that are expected over the next few years. Scala maintained his Outperform rating on Eli Lilly shares, which are down 5.5% in pre-market trading to $81.28.
04/17/17
LEER
04/17/17
NO CHANGE
LEER
Outperform
Incyte Baricitinib CRL setback surprising, says Leerink
Leerink analyst Michael Schmidt notes that Eli Lilly (LLY) and Incyte (INCY) announced that the FDA has issued a complete response letter, or CRL, for the New Drug Application of baricitinib for the treatment of moderate-to-severe rheumatoid arthritis. The analyst says this is "surprising news," given that the drug is already approved and marketed in Europe based on the same data package and is a setback for Incyte and its partner Eli Lilly. Further, Schmidt expects Incyte's shares to be weak given that a 1 year U.S. approval delay seems now likely, in a best case scenario. He reiterates an Outperform rating on Incyte's shares.
04/17/17
04/17/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Eli Lilly (LLY) was downgraded to Equal Weight from Overweight at Morgan Stanley and to Underperform from Market Perform at BMO Capital. 2. Incyte (INCY) downgraded to Neutral from Overweight at Piper Jaffray with analyst Joshua Schimmer citing the complete response letter from the FDA for baricitinib, indicating a need to determine appropriate doses. This setback could take years and lead to approval of only the lower dose, leaving potentially little differentiation from Pfizer's (PFE) rheumatoid arthritis treatment Xeljanz," Schimmer tells investors in a research note. The analyst prefers to wait for a "cleaner entry point" into the shares. 3. KKR (KKR) downgraded to Neutral from Buy at Citi with analyst William Katz saying he views the stock's valuation relative to peers as less attractive at current levels. 4. Monster Beverage (MNST) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Judy Hong saying she expects shares to be range-bound near-term due to soft core Monster sales trends in the US. 5. PNC Financial (PNC) downgraded to Hold from Buy at Rafferty Capital with analyst Richard Bove saying bank stock valuations are too high and growth is lacking. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/17/17
LEER
04/17/17
NO CHANGE
LEER
Outperform
Leerink sees attractive buying opportunity in Eli Lilly ahead of Q1 results
While noting that Eli Lilly's (LLY) stock is under pressure following the news that baricitinib did not receive FDA approval with the Agency expressing concerns over dosing and safety, Leerink sees an "attractive buying opportunity" ahead of Q1 results given "strong trends" in the company's new product launches, particularly for high-margin Trulicity and Taltz. Further, the firm says that while baricitinib could face a 12-18 month delay in the U.S., it is already approved in EU and is not the biggest valuation driver due to the 18% royalty it pays to partner Incyte (INCY). Leerink has Outperform ratings on Eli Lilly and Incyte's shares.
ARNC Arconic
$26.00

-0.11 (-0.42%)

04/18/17
JPMS
04/18/17
INITIATION
Target $29
JPMS
Neutral
Arconic initiated with a Neutral at JPMorgan
JPMorgan analyst Seth Seifman started Arconic with a Neutral rating and $29 price target. The analyst views Klaus Kleinfeld's resignation as a plus and sees "significant" earnings growth ahead, but notes the stock is already up 44% year-to-date.
04/18/17
04/18/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Arconic (ARNC) initiated with a Neutral at JPMorgan. 2. Priceline (PCLN) coverage transferred with an Outperform at Macquarie. 3. Interpublic Group (IPG) was initiated with an Outperform at Evercore ISI while Omnicom (OMC) was initiated with an In Line. 4. Alteryx (AYX) was initiated with an Outperform at William Blair, Raymond James, JMP Securities, and Cowen, an Overweight at Pacific Crest, a Buy at Goldman Sachs, and a Neutral at JPMorgan. 5. Synacor (SYNC) initiated with a Buy on upcoming growth at Canaccord. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/31/17
LBOW
03/31/17
INITIATION
LBOW
Neutral
Arconic initiated with a Neutral at Longbow
Longbow analyst Christopher Olin initiated Arconic with a Neutral.
03/29/17
COWN
03/29/17
INITIATION
Target $25
COWN
Market Perform
Arconic initiated with a Market Perform at Cowen
Cowen analyst Gautam Khanna initiated Arconic (ARNC) with a Market Perform rating and $25 price target, saying the bulls' contention that the 600-900bp margin gap between Arconic's EPS segment and competitor Precision Castparts (PCP) can be eliminated by replacing Arconic's CEO is unrealistic. The stock is not "cheap," even if management changes, Khanna argues.
FOX 21st Century Fox
$30.22

-0.33 (-1.08%)

04/04/17
PIVT
04/04/17
NO CHANGE
Target $36
PIVT
Buy
Boycotts of O'Reilly Factor likely manageable for now, says Pivotal Research
Pivotal Research analyst Brian Wieser said advertiser boycotts of O'Reilly Factor are likely manageable and only slightly negative at this time, but added that a more significant concern is the potential for this to impact Ofcom's "fit and proper" test related to Fox's (FOXA) proposed takeover of Sky (SKYAY). Wieser, who views the Sky acquisition as a favorable strategic combination, would sees the U.K. regulator not allowing the transaction to proceed as a negative. However, he keeps a Buy rating and $36 price target on Fox shares.
12/19/16
BMUR
12/19/16
NO CHANGE
Target $33
BMUR
Buy
21st Century Fox has low probability of takeover, says Brean Capital
Brean Capital analyst Alan Gould continues to recommend Twenty-First Century Fox, as he believes the shares are quite attractive at current levels. Gould said the stock trades at the lowest revenue multiple, highest free cash flow yield, and the greatest discount to private market value in the group, adding that the company has a low probability of takeover given the Murdoch family's 39% voting control. Gould reiterated his Buy rating and $33 price target on Twenty-First Century Fox shares.
04/04/17
RSBL
04/04/17
INITIATION
Target $33
RSBL
Neutral
21st Century Fox initiated with a Neutral at Rosenblatt
Rosenblatt started 21st Century Fox with a Neutral rating and $33 price target.
01/03/17
01/03/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Evercore ISI analyst Vijay Jayant upgraded Disney (DIS) to Buy from Hold, named it Top Pick for 2017, and raised its price target to $120 from $103. Jayan believes Disney's valuation reflects well-understood short-term growth challenges at ESPN and tough Studio and Consumer Products growth comparisons. 2. Wells Fargo analyst Marci Ryvicker upgraded 21st Century Fox (FOXA) to Outperform saying the market could be surprised by the synergies from the Sky deal. The analyst also believes concerns over the Regional Sports Networks being excluded from the streaming bundles are overblown. She expects consensus estimates to go up not down and raised her price target range for the shares to $33-$35 from $28-$30. 3. Citi analyst Michael Rollins upgraded Verizon (VZ) Communications to Buy from Neutral and raised his price target for the shares to $60 from $55. 4. Evercore ISI upgraded PACCAR (PCAR) to Buy from Hold and raised its price target to $77 from $59, with analyst David Raso saying he is incrementally bullish on the Industrials and Machinery sector since his pre-US election sector upgrade. 5. Credit Suisse upgraded Xerox (XRX) to Outperform from Neutral. Analyst Kulbinder Garcha changed his rating following the Conduent (CNDT) spin-off citing a more focused printing business, potential upside to cost savings, and management's realistic vision and a well laid out long-term strategy to offset end market decline. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
FOXA 21st Century Fox
$30.70

-0.37 (-1.19%)

03/27/17
SBSH
03/27/17
INITIATION
Target $25
SBSH
Buy
WWE initiated with a Buy at Citi
Citi analyst Jason Bazinet started WWE (WWE) with a Buy rating and $25 price target. WWE's transition to a web-based subscription model should result in better growth through 2020 and increases the company's strategic value to likely suitors, such as 21st Century Fox (FOXA), Comcast (CMCSA) and Formula One (LMCA), the analyst contends.
02/01/17
MOFT
02/01/17
UPGRADE
MOFT
Buy
21st Century Fox upgraded to Buy from Neutral at MoffettNathanson
STRP Straight Path
$109.59

0.43 (0.39%)

04/10/17
RHCO
04/10/17
NO CHANGE
RHCO
SunTrust views AT&T deal as highlighting 5G momentum
SunTrust analyst Greg Miller believes AT&T's (T) acquisition of Straight Path (STRP) highlights the "strong momentum" on early 5G network development plans, including fixed wireless. He believes the news is positive for infrastructure companies including Crown Castle (CCI), Zayo Group (ZAYO), Uniti Group (UNIT) and ultimately American Tower (AMT) and SBA Communications (SBAC) in later-stage 5G deployments.
T AT&T
$39.93

-0.43 (-1.07%)

04/18/17
RHCO
04/18/17
INITIATION
Target $40
RHCO
Hold
AT&T initiated with a Hold at SunTrust
SunTrust analyst Greg Miller started AT&T with a Hold rating and $40 price target. The analyst prefers cable names over wireless given a "more supportable growth outlook and greater potential to preserve margins."
04/17/17
OPCO
04/17/17
NO CHANGE
OPCO
FCC decision makes T-Mobile 'a much more attractive' target, says Oppenheimer
Oppenheimer analyst Timothy Horan notes that the FCC announced 50 winners of the 70 MHZ of broadcast spectrum. While the analyst says this was in line with his below-market expectations, he notes that T-Mobile (TMUS) winning 45% of the spectrum was above. Horan believes this is a game-changer for the company long-term as it will be able to match coverage/quality with Verizon (VZ)/AT&T (T) over time, and makes it "a much more attractive" takeover target.
04/19/17
04/19/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. ING Group (ING) initiated with a Buy at Jefferies. 2. T-Mobile (TMUS) was initiated with a Buy at SunTrust while Sprint (S), Verizon (VZ), and AT&T (T) were initiated with a Hold. 3. DXC Technology (DXC) initiated with an Overweight at JPMorgan. 4. LendingClub (LC) coverage resumed with a Hold at Stifel. 5. Halliburton (HAL) and Schlumberger (SLB) were initiated with a Buy at HSBC while Baker Hughes (BHI) was initiated with a Hold. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ALR Alere

03/01/17
RAJA
03/01/17
NO CHANGE
RAJA
Market Perform
Alere filing delay should not be surprise, says Raymond James
Raymond James analyst Nicholas Jansen says that while the annual filing delay is not a headline Alere (ALR) shareholders wanted to see given the company's current battle with Abbott (ABT), the revision just relates to timing, not "bad revenue," and is immaterial in totality relative to a $2.5B revenue base. Alere's annual filing was unlikely to include a full remediation of internal control weakness, so this issue, while disappointing, should not be a surprise, Jansen tells investors in a research note. He keeps a Market Perform rating on the shares. Alere in early trading is down 3%, or $1.27, to $37.03.
04/13/17
RBCM
04/13/17
NO CHANGE
RBCM
Abbott Q1 results should beat expectations, says RBC Capital
RBC Capital expects Abbott's (ABT) Q1 results to beat expectations. However, the firm does not expect the company to raise its 2017 guidance and says that its Alere (ALR) deal "remains an overhang."
04/17/17
COWN
04/17/17
NO CHANGE
Target $48
COWN
Outperform
Cowen views Alere deal closing positively for Abbott
Cowen analyst Joshua Jennings views the amended terms of Abbott's (ABT) deal with Alere (ALR) positively as it puts an end to controversial pre-closing saga and allows Abbot to become the leading point of care diagnostics provider. The amended deal lowered the takeover price and the closing will allow investors to focus now on the fundamentals of the combined entity. Jennings reiterated his Outperform rating and $48 price target on Abbot shares.
03/01/17
BTIG
03/01/17
NO CHANGE
Target $44
BTIG
Buy
Alere filing delay creates additional uncertainty, says BTIG
BTIG analyst Dane Leone notes Alere yesterday delayed the filing of its annual report due to inappropriate timing of revenue recognition in Korea, and possibly Japan. While the absolute dollar amounts are not concerning, the residual material weakness in controls creates additional uncertainty, Leone tells investors in a research note. He keeps a Buy rating on the shares with a $44 price target.
ABT Abbott
$43.53

-0.45 (-1.02%)

04/13/17
COWN
04/13/17
NO CHANGE
Target $48
COWN
Outperform
Abbott may be able to work toward MR-safe approval despite warning, says Cowen
While it is possible that the FDA warning letter to Abbott disclosed yesterday may prevent approval of MR-safe high-powered devices from coming this year, as expected, it is likely that submissions related to the devices will be PMA supplements, not full PMAs, which is "an important nuance," according to Cowen analyst Joshua Jennings. There is a historical precedent for a PMA supplement receiving FDA approval when a warning letter exists, namely St. Jude's approval for Optisure, said Jennings, who adds that resolving the warning letter is a top priority for Abbott regardless of the filings' pathway. He keeps an Outperform rating on Abbott shares.
04/13/17
COWN
04/13/17
NO CHANGE
Target $90
COWN
Outperform
Cowen sees Apple threat to Dexcom as 'only hype/hope' at this point
The slide in Dexcom (DXCM) shares this morning is "seemingly due" to a report saying Apple (AAPL) is working on a non-invasive glucose sensor, said Cowen analyst Doug Schenkel, but he cautions that other companies have been trying to do the same for decades and all have failed. While you can " never say never," Schenkel views it as "extremely unlikely" that Apple has succeeded and he will not be worried about this threat to Dexcom until he sees data, he tells investors. Beyond today's dip, a move in Dexcom shares from their recent highs is due to heightened investor focus on nearer-term competitive products coming later this year from Medtronic (MDT) and Abbott (ABT), noted Schenkel, who keeps an Outperform rating and $90 price target on Dexcom.
04/20/17
RBCM
04/20/17
NO CHANGE
RBCM
Abbott Q1 results should ease concerns, says RBC Capital
RBC Capital analyst Glenn Novarro says that Abbott's Q1 results represented a "solid beat" and should ease concerns over the risks posed by its integration of St. Jude and its China nutritional business. The analyst keeps a $50 price target and an Outperform rating on the stock.
BABA Alibaba
$113.11

0.15 (0.13%)

04/20/17
STPT
04/20/17
DOWNGRADE
STPT
Reduce
Alibaba downgraded to Reduce from Buy at Standpoint Research
04/18/17
BNCH
04/18/17
INITIATION
Target $140
BNCH
Buy
Alibaba initiated with a Buy at Benchmark
Benchmark analyst Fawne Jiang initiated Alibaba with a Buy rating and $140 price target.
04/18/17
KEYB
04/18/17
NO CHANGE
KEYB
Alibaba outlook has improved, says KeyBanc
KeyBanc is more confident in Alibaba's outlook after taking a trip to China recently. The firm expects the company 's monetization to be boosted by "improving personalized recommendations and ongoing ad budget shifts." It keeps a $134 price target and an Overweight rating on the stock.
04/20/17
04/20/17
DOWNGRADE

Alibaba downgraded to Reduce on valuation at Standpoint Research
As previously reported, Standpoint analyst Ronnie Moas downgraded Alibaba to Reduce from Buy, citing valuation with the stock now trading at an all-time high.
MGI MoneyGram
$17.79

0.12 (0.68%)

01/26/17
FANA
01/26/17
DOWNGRADE
FANA
Equal-Weight
MoneyGram downgraded to Equal-Weight from Overweight at First Analysis
First Analysis analyst Lawrence Berlin downgraded MoneyGramto Equal-Weight from Overweight following its deal to be acquired by Ant Financial. He expects the transaction to be completed at the announced price, though he sees greater than normal uncertainty since the acquirer is Chinese and the Trump administration "may look critically" at the deal.
03/14/17
RHCO
03/14/17
NO CHANGE
RHCO
Buy
SunTrust says buy Euronet on MoneyGram deal selloff
Euronet's (EEFT) $1.8B offer to acquire MoneyGram (MGI) is "superior in all ways" to Ant Financial's, which is owned by Alibaba (BABA), SunTrust analyst Andrew Jeffrey tells investors in a research note. He expects shares of Euronet to come under pressure this morning "as many investors simply do not like global remittance." Jeffrey recommends using the weakness to buy Euronet, however, as he feels the company has a differentiated franchise and superior management and growth strategy.
03/14/17
BTIG
03/14/17
NO CHANGE
BTIG
BTIG says Western Union positive reaction to MoneyGram news makes sense
BTIG analyst Mark Palmer said he believes the uptick in Western Union (WU) shares after the announcement of Euronet's (EEFT) offer to buy competitor MoneyGram (MGI) makes some sense as Euronet may be seen as less of a competitive threat than Alibaba's (BABA) Ant Financial, which previously struck a deal to buy MoneyGram, and the bid underscores the attractiveness and potential of the global remittance space. However, speculation that if Ant was unsuccessful in its effort to acquire MoneyGram it could look to acquire VeriFone (PAY) or Green Dot (GDOT) "makes less sense," said Palmer.
01/30/17
FLTL
01/30/17
DOWNGRADE
FLTL
Hold
MoneyGram downgraded to Hold from Buy at Feltl
Feltl downgraded MoneyGram following its deal to be acquired by Ant Financial for $13.25 per share.
CAB Cabela's
$56.94

-0.11 (-0.19%)

10/04/16
LEHM
10/04/16
DOWNGRADE
Target $64
LEHM
Equal Weight
Cabela's downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Matthew McClintock downgraded Cabela's to Equal Weight saying the takeover offer from Bass Pro Shops fully values the company's assets. The analyst raised his price target for the shares to $64 from $50.
03/30/17
SPHN
03/30/17
NO CHANGE
Target $64
SPHN
Overweight
TSYS could see 'a small benefit' from Cabela's sale, says Stephens
Stephens analyst Brett Huff thinks TSYS (TSS) could see "a small benefit" from the sale of Cabela's (CAB). After being delayed by regulatory approvals, The Wall Street Journal is reporting that Bass Pro would buy the retail ops, Synovus (SNV) would buy bank/co-branded credit card portfolio, and in turn selling the portfolio to Capital One (COF), he notes. The analyst points out that TSYS is Capital One's card issuing processor, and says he thinks the about 2M active cards would move to TSYS' platform. Huff reiterates an Overweight rating and $64 price target on TSYS's shares.
03/02/17
NRCS
03/02/17
NO CHANGE
NRCS
Northcoast says to buy Cabela's
Northcoast analyst Chuck Cerankosky said Cabela's shares are trading below $48, well below Bass Pro's $65.50 offer and believes his $60 price target is reasonable and provides room for a potential final deal price adjustment. He strongly believes investors have placed too much too much concern around the government agencies and said other banks are interested in Cabela's Visa card business, World's Foremost Bank, which Capital One intends to purchase.
10/03/16
MKMP
10/03/16
DOWNGRADE
MKMP
Neutral
Cabela's downgraded to Neutral from Buy at MKM Partners
MKM Partners downgraded Cabela's to Hold following the acquisition by Bass Pro Shops for $65.50 per share.
SNV Synovus
$41.89

-0.22 (-0.52%)

01/09/17
WELS
01/09/17
UPGRADE
WELS
Market Perform
Synovus upgraded to Market Perform from Underperform at Wells Fargo
Wells Fargo analyst Jared Shaw upgraded Synovus to Market Perform citing a better outlook for economic growth as well as his expectations for four rate hikes over the next 24 months. The analyst raised his price target range for the shares to $36-$38 from $28-$30.
01/09/17
HOVD
01/09/17
DOWNGRADE
HOVD
Market Perform
Synovus downgraded to Market Perform from Outperform at Hovde Group
03/03/17
EVER
03/03/17
DOWNGRADE
EVER
In Line
Synovus downgraded to In Line from Buy at Evercore ISI
CAH Cardinal Health
$72.50

-0.81 (-1.10%)

04/18/17
LEER
04/18/17
NO CHANGE
LEER
Market Perform
Cardinal Health struggles may be benefitting AmerisourceBergen, says Leerink
Leerink analyst David Larsen noted that Cardinal Health (CAH) pointed to generic pricing and sell-side pressure and incremental investments as primary reasons for its FY18 and FY19 adjusted EPS forecasts missing expectations, but he believes there may be other challenges the business is facing too. Cardinal's loss of Prime Therapeutics and Walgreens' (WBA) recent wins from CVS Health (CVS) are other factors that may have hurt Cardinal, said Larsen, who added that both of those will benefit AmerisourceBergen (ABC). The analyst, who also said he is incrementally more cautious on McKesson (MCK) and Owens & Minor (OMI) after Cardinal's call, has an Outperform rating on AmerisourceBergen and Market Perform ratings on Cardinal Health, McKesson and O&M.
04/21/17
LEER
04/21/17
NO CHANGE
Target $72
LEER
Market Perform
Cardinal Health price target lowered to $72 from $81 at Leerink
Leerink analyst David Larsen lowered his price target for Cardinal Health (CAH) to $72 from $81 to account for the updated guidance provided by management, as well as the acquisition of Medtronic's (MDT) Patient Recovery business. The analyst reiterates a Market Perform rating on Cardinal Health's shares.
04/19/17
WBLR
04/19/17
DOWNGRADE
WBLR
Market Perform
William Blair downgrades Cardinal Health on 'alarming' pharma outlook
William Blair analyst John Kreger downgraded Cardinal Health (CAH) to Market Perform from Outperform saying that while the Medtronic (MDT) asset purchase is a positive step, yesterday's guidance update suggests that pressures on the pharma distribution business are continuing. The analyst views the outlook as "alarming" and now sees a lower earnings outlook for FY18 and beyond.
04/19/17
WBLR
04/19/17
DOWNGRADE
WBLR
Market Perform
Cardinal Health downgraded to Market Perform from Outperform at William Blair
William Blair analyst John Kreger downgraded Cardinal Health to Market Perform.
MDT Medtronic
$80.48

-0.54 (-0.67%)

04/06/17
WELS
04/06/17
NO CHANGE
WELS
Medtronic data 'mostly encouraging,' says Wells Fargo
Wells Fargo says that the results of a trial of Medtronic's HVAD left ventricular assist device for destination therapy was "mostly positive." Even though the device missed the primary endpoint of neurological events, it showed superiority on the more traditional endpoint of survival at 12 months without debilitating illness , while the stroke rates of patients that had it were similar to those of Abbott's (ABT) HeartMate and hemorrhagic stroke rates fell 50% versus a previous trial. Wells keeps an Outperform rating on Medtronic.
04/07/17
SBSH
04/07/17
NO CHANGE
Target $93
SBSH
Buy
Citi makes Medtronic top sector pick after endocrinologist survey
Citi analyst Amit Hazan says his firm's semi-annual survey of 40 U.S. endocrinologists has come back "significantly more positive" for Medtronic (MDT). The analyst makes the stock his top pick in Medical Supplies for the rest of 2017, replacing Boston Scientific (BSX) and Intuitive Surgical (ISRG). The survey shows "significant" new shares gains for Medtronic in pumps and the CGM segment, Hazan tells investors in a research note. The analyst keeps a Buy rating on Medtronic with a $93 price target.
VIRT Virtu Financial
$16.05

-0.4 (-2.43%)

04/03/17
WELS
04/03/17
DOWNGRADE
WELS
Market Perform
KCG Holdings downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Christopher Harris downgraded KCG Holdings (KCG) to Market Perform saying the offer from Virtu Financial (VIRT) "seems fair." The analyst admits that he has "no edge" on the deal's prospects. His $16-$18 price target range for KCG reflects the company's standalone value.
04/21/17
UBSW
04/21/17
NO CHANGE
Target $19
UBSW
Buy
Virtu Financial price target raised to $19 from $17 at UBS
UBS analyst Alex Kramm raised his price target on Virtu Financial (VRTU) to $19 from $17 following the company's agreement to buy KCG Holdings (KCG). The analyst notes Virtu gains access to KCG's institutional client base and sees 25% accretion in a tough environment and more if trends improve. Kramm reiterated his Buy rating on Virtu shares.
03/16/17
UBSW
03/16/17
NO CHANGE
Target $20
UBSW
Buy
Virtu deal for KCG has significant execution risk, says UBS
UBS analyst Alex Kramm sees the potential for significant execution risk if Virtu Financial (VIRT) succeeds in its bid for KCG Holdings (KCG). Kramm questions whether the bid for KCG signals Virtu has lost patience with the macro environment and with its attempt at growth if they are willing to bring on a decent amount of execution risk. As a result, the analyst feels perhaps Virtu was not as well positioned as once thought. However, Kramm maintained his Buy rating and $20 price target on Virtu shares.
KCG KCG Holdings

07/14/16
07/14/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Procter & Gamble (PG) upgraded to Buy from Neutral at UBS with analyst Stephen Powers saying the risk/reward is positive given the company's changes over the past six months. 2. Dick's Sporting (DKS) upgraded to Outperform from Sector Perform at RBC Capital with the firm saying it thinks that the company has a number of potential positive catalysts going forward, including reduced disruption from the Sports Authority's liquidation in the second quarter and third quarter and potential benefits from the liquidation next year, along with reduced spending on e-commerce in 2017. 3. GlaxoSmithKline (GSK) upgraded to Buy from Hold at Jefferies with analyst Jeffrey Holford saying fears of a dividend cut are overdone and the company's improving yield quality will continue to attract investors. 4. Southern Company (SO) upgraded to Overweight from Equal Weight at Barclays with analyst Daniel Ford saying the risk/reward is improving as it transforms to an infrastructure company. 5. Barrick Gold (ABX) and Randgold (GOLD) upgraded to Buy from Hold and Kinross Gold (KGC) upgraded to Hold from Underperform at Jefferies with analyst Christopher LaFemina upgrading the stocks after his firm increased its gold price forecasts to reflect ongoing elevated macro risk. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
GNC GNC Holdings
$8.24

-0.54 (-6.15%)

04/19/17
JPMS
04/19/17
NO CHANGE
Target $12
JPMS
Neutral
GNC Holdings price target raised to $12 from $10 at JPMorgan
JPMorgan analyst Christopher Horvers raised his price target for GNC Holdings to $12 saying yesterday's earnings and comp beat "take off the table the terminal value question that many investors were focused on." The question, however, is if the traffic is sustainable and whether GNC can turn the decline in average ticket up, Horvers tells investors in a post-earnings research note. The analyst keeps a Neutral rating on the shares.
02/15/17
MACQ
02/15/17
NO CHANGE
Target $20
MACQ
Outperform
GNC Holdings shares pricing in 'draconian' outcomes, says Macquarie
Macquarie analyst Bob Summers said GNC Holdings' Q4 and near-term results will prove challenging but management has made decisions that will significantly increase the company's long-term potential to succeed by simplifying pricing and having consistent in-store and online pricing. The analyst said these efforts will pressure margins, but shares are pricing in "draconian" outcomes with shares trading at just over 4x P/E. Summers expects free cash flow to remain positive, which could be further enhanced by cutting the dividend and notes there are no near-term debt maturities to create credit risk. The analyst said even a "slight bend" in same-store sales trends could produce a dramatic positive outcome and reiterates his Outperform rating and $20 price target on GNC Holdings.
01/19/17
GSCO
01/19/17
DOWNGRADE
GSCO
Sell
GNC Holdings downgraded to Sell on brand re-launch, competition at Goldman
As previously reported, Goldman downgraded GNC Holdings to Sell from Neutral and lowered its price target to $8 from $12. Analyst Stephen Tanal believes GNC's brand re-launch, which it cut prices meaningfully across half of its assortment and ended its Gold Card loyalty program, will weigh on profitability to a much greater degree than consensus estimates reflect. The analyst expects persistent same-store-sales declines to persist given share losses to conventional retailers including grocers, drug stores, warehouse/clubs, as well as online challengers.
01/19/17
GSCO
01/19/17
DOWNGRADE
GSCO
Sell
GNC Holdings downgraded to Sell from Neutral at Goldman
MS Morgan Stanley
$41.80

-0.7 (-1.65%)

03/29/17
DBAB
03/29/17
UPGRADE
Target $47
DBAB
Buy
Morgan Stanley upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Matt O'Connor upgraded Morgan Stanley (MS) to Buy citing the recent 10% pullback in the shares and his optimism for capital markets beyond Q1. Continued successful execution within FICC will support a higher multiple, O'Connor tells investors in a research note. He raised his price target for Morgan Stanley shares to $47 from $43. Goldman Sachs (GS) and Wells Fargo (WFC) are the analyst's other top picks among the U.S. Banks.
03/29/17
03/29/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Morgan Stanley (MS) upgraded to Buy from Hold at Deutsche Bank with analyst Matt O'Connor citing the recent 10% pullback in the shares and his optimism for capital markets beyond the first quarter. 2. Capital One (COF) upgraded to Buy from Neutral at Nomura with analyst Bill Carcache saying most card issuers have reduced their sub-prime exposure since 2011, but Capital One has increased its subprime mix by 500 bps and is positioned to reap the rewards. Carcache expects Capital One's net income and earning to inflect in 2017 and 2018 with healthy high-single-digit card loan growth continuing, while the need to build reserves abates. The analyst adds, even with no Trump tax or regulatory policy tailwinds, Capital One should put up double-digit earnings growth in 2017 and 2018. 3. Ericsson (ERIC) upgraded to Outperform from Market Perform at Bernstein with analyst Pierre Ferragu saying the company's restructuring plan skews the risk/reward to the upside. 4. Chemours (CC) upgraded to Buy from Hold at Jefferies with analyst Laurence Alexander saying while the stock has rallied as a trade on cyclical leverage and litigation relief, structural improvements in TiO2 and fluoropolymers could bring further upside. 5. Vertex (VRTX) upgraded to Outperform from Market Perform at BMO Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/04/17
04/04/17
NO CHANGE

Mrogan Stanley recommends buying large banks on weakness after Q1 results
Morgan Stanley analyst Betsy Graseck expects most large banks she covers to report weaker than expected Q1 results. However, the analyst recommends that investors buy the large-cap bank stocks on weakness, as she expects them to benefit from "stronger capital return, easing regulation, lower taxes and higher rates in 2H17," along with an improved GDP outlook and strong expense management. Graseck identifies Citi (C) as her top pick heading into the quarter, as she expects its Q1 results to beat expectations, driven by strength in emerging markets and "repositioning investments" that have started to beat fruit. She expects the bank to get a boost from CCAR in June and says that it is "the biggest beneficiary of easing regulation." Other publicly traded companies in the space include Bank of America (BAC), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC).
04/06/17
EVER
04/06/17
NO CHANGE
EVER
Glass-Steagall return wouldn't find support in Congress, says Evercore ISI
After media reports claimed White House economic adviser Gary Cohn supports rules to make banks split their consumer lending units from their investment divisions, which hints at a return of the "Glass-Steagall" law that was ended by President Clinton and a Republican Congress in 1999, Evercore ISI analyst Terry Haines said there is little support in Congress for a return of the law. Any new bank regulations can't "be done with the stroke of a pen" and will have to go through the usual regulatory process, added Haines. Publicly traded large banks include Bank of America (BAC), Citi (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC).
ISRG Intuitive Surgical
$813.43

-1.02 (-0.13%)

04/19/17
STFL
04/19/17
NO CHANGE
STFL
Intuitive Surgical reported 'extremely robust' Q1 results, says Stifel
Stifel analyst Rick Wise says that Intuitive Surgical's Q1 results were "extremely robust." He says that the results were "highlighted" by the 18% growth in its procedures, versus the consensus outlook of 11%-12%., as well as by its "strong system sales" and higher than expected gross margins The analyst believes that the company will be helped by its decision to launch a lower cost robotic surgery system ,and he raised his price target on the shares to $850 from $800 while keeping a Buy rating on the stock.
04/19/17
LEER
04/19/17
NO CHANGE
Target $850
LEER
Outperform
Intuitive Surgical price target raised to $850 from $840 at Leerink
Leerink analyst Richard Newitter raised his price target for Intuitive Surgical to $850 from $840 on slightly higher cash/share assumption. The analyst reiterates an Outperform rating on Intuitive Surgical following Q1 which saw over 18% procedure growth that was well-above expectations, along with gross margin upside, and a higher 2017 outlook for both.
04/19/17
BOFA
04/19/17
NO CHANGE
Target $900
BOFA
Buy
Intuitive Surgical price target raised to $900 from $800 at BofA/Merrill
BofA/Merrill analyst Bob Hopkins raised Intuitive Surgical's (ISRG) price target to $900 following the Q1 report of volume growth above expectations and the announcement of an entirely new, unexpected robotic platform, the da Vinci X. The analyst believes the new dA Vinci X platform could drive a significant Si upgrade cycle and expand the company's foot print into more cost sensitive accounts that Medtronic (MDT) may have targeted, materially impacted 2018/19 revenue growth. Hopkins rates Intuitive Surgical a Buy.
04/19/17
STPT
04/19/17
DOWNGRADE
STPT
Sell
Standpoint double downgrades Mazor on Intuitive-like valuation
Standpoint analyst Ronnie Moas double downgraded Mazor Robotics (MZOR) to Reduce from Buy with the stock up 63% since he initiated coverage on July 8 of last year. The stock's valuation, at 11 times sales, is similar to Intuitive Surgical (ISRG), but Mazor is yet to turn a profit, the analyst adds. Moas says he'd likely reinstate his Buy recommendation if the stock were to retreat to the $28 level. Mazor is up 6% to $32.98 in morning trading following Intuitive's better than expected earnings report.
AXP American Express
$79.59

-0.43 (-0.54%)

04/20/17
JPMS
04/20/17
NO CHANGE
Target $94
JPMS
Overweight
JPMorgan says American Express 'becoming great again,' ups target to $94
In a research note titled "Becoming Great Again," JPMorgan analyst Richard Shane raised his price target for American Express shares to $94 from $90 following the company's Q1 results. The analyst expects a positive reaction when the market opens. The earnings beat was driven by strong top-line growth while American Express' loan growth continues ahead of the industry, Shane tells investors in a post-earnings research note. He keeps an Overweight rating on the shares.
04/20/17
OPCO
04/20/17
NO CHANGE
Target $93
OPCO
Outperform
American Express fundamentals already shifting more positive, says Oppenheimer
Oppenheimer analyst Ben Chittenden continues to like the American Express story and says the Q1 results only reinforce why he likes it. The analyst believes this is a company where sentiment is very negative yet the fundamentals are already shifting more positive. While competition is clearly more intense post crisis, American Express is managing through it, he adds. Chittenden reiterates an Outperform rating and $93 price target on the shares.
03/24/17
TIGR
03/24/17
INITIATION
TIGR
Neutral
American Express initiated with a Neutral at Tigress Financial
Tigress Financial analyst Ivan Feinseth initiated American Express with a Neutral saying business performance remains weak due to increasing competition and the loss of its largest customer and views shares as fairly valued.
03/24/17
03/24/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. American Express (AXP) initiated with a Neutral at Tigress Financial. 2. Zosano Pharma (ZSAN) initiated with an Overweight at Piper Jaffray. 3. SkyWest (SKYW) initiated with an In-Line at Imperial Capital. 4. Statoil (STO) initiated with an Underperform at Macquarie. 5. Cogent (CCOI) initiated with a Buy at Deutsche Bank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
QCOM Qualcomm
$52.50

-0.16 (-0.30%)

04/20/17
SBSH
04/20/17
NO CHANGE
Target $60
SBSH
Neutral
Qualcomm royalty rates will continue to decline, says Citi
Citi analyst Christopher Danely says that while Qualcomm's (QCOM) Q2 results topped expectations, its Q3 guidance missed due to lower royalty payments. The analyst believes Qualcomm's royalty rates will continue to decline and that the NXP Semiconductors (NXPI) acquisition "will be fraught with problems." Danely keeps a Neutral rating on the shares with a $60 price target.
04/20/17
UBSW
04/20/17
NO CHANGE
Target $58
UBSW
Neutral
Qualcomm guidance not as bad as feared, says UBS
UBS analyst Stephen Chin noted Qualcomm (QCOM) reported a strong Q2 beat but he maintained his Neutral rating due to uncertainty over future Apple (AAPL) payments as its lawsuit remains unresolved and it disclosed there is a new underpaying licensee. Chin said fundamentals remain mixed near-term, but added that the company's guidance was not as bad as feared. Chin has a $58 price target on Qualcomm shares.
04/21/17
ARGS
04/21/17
NO CHANGE
ARGS
Qualcomm weakness creates 'deep value' opportunity, says Argus
Argus analyst Jim Kelleher says that Qualcomm's Q2 results showed that the company's fundamentals were "solid." The analyst says that the company is seeing "solid top and bottom line trends," creating "a deep value opportunity." He recommends buying the stock at current levels.
04/20/17
WELS
04/20/17
NO CHANGE
WELS
Market Perform
Apple has 'modest' margin risk from ongoing Qualcomm fight, says Wells Fargo
Wells Fargo analyst Maynard Um noted that Apple (AAPL) has acknowledged it withheld payments to its contract manufacturers in the amount that it felt Qualcomm (QCOM) owed it under a separate cooperation agreement, but that Qualcomm "seems to believe," based on its earnings call comments, that the manufacturers will eventually pay what's contractually owed. With the cooperation agreement having ended at the end of 2016, it remains unclear if Apple will have to pay its contract manufacturers the cited $1B over three quarters, which leaves "modest risk" on the possibility for an increase in cost of goods and associated hit to gross margins, said Um, who has a Market Perform rating on Apple shares.
CSX CSX
$50.77

1.21 (2.44%)

04/21/17
SPHN
04/21/17
NO CHANGE
Target $58
SPHN
Overweight
CSX price target raised to $58 from $44 at Stephens
Stephens analyst Justin Long raised his price target for CSX to $58 from $44 following Q1 results. The analyst reiterates an Overweight rating on the shares.
04/21/17
UBSW
04/21/17
NO CHANGE
Target $60
UBSW
Buy
CSX upside potential attractive and shares should be bought, says UBS
UBS analyst Thomas Wadewitz noted CSX delivered a Q1 upside surprise. Also, given the earnings commentary, he believes the company's complex network of rails translates into a greater cost savings opportunity as the flow of traffic is simplified and number of work events/touches is reduced. Wadewitz reiterated his Buy rating and raised his price target to $60 from $57 on CSX shares.
04/21/17
04/21/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Costco (COST) upgraded to Overweight from Equal Weight at Barclays with analyst Karen Short citing a survey by the firm where results showed analytically that Costco (COST) is "very protected" from Amazon (AMZN). 2. CSX (CSX) was upgraded to Buy from Hold at Aegis and to Outperform from Market Perform at Raymond James. 3. Gigamon (GIMO) upgraded to Buy from Hold at Stifel with analyst Patrick Newton citing valuation and his belief that the company has a number of potential positive catalysts, including the 100G upgrade cycle at T-Mobile (TMUS), in-line SSL decryption, and the potential for reduced competition from Ixia (XXIA). 4. Skechers (SKX) upgraded to Buy from Neutral at B. Riley with analyst Jeff Van Sinderen citing "strong" international growth and worldwide comps following the company's better than expected first quarter results. The analyst raised his price target for the shares to $32 from $28. 5. Quest Diagnostics (DGX) upgraded to Outperform from Market Perform at Raymond James with analyst Nicholas Jansen saying Quest has delivered two strait quarters of high single digit adjustment EBIT growth and sees room for sustained mid-to-high single digit growth driven by improved commercial execution, strengthening health system relationships and outreach deals, and invigorate programs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/21/17
AGIS
04/21/17
UPGRADE
Target $64
AGIS
Buy
CSX upgraded to Buy from Hold at Aegis
Aegis analyst Jeffrey Kauffman upgraded CSX to Buy from Hold citing the increased clarity on CEO Hunter Harrison's improvement program following the company's Q1 results and FY guidance. Kauffman also increased his 2020 EPS forecast for CSX and raised his price target on the shares to $64 from $50.
HON Honeywell
$127.08

3.31 (2.67%)

02/21/17
JEFF
02/21/17
NO CHANGE
Target $141
JEFF
Buy
Honeywell price target raised to $141 from $133 at Jefferies
Jefferies analyst Howard Rubel raised his price target for Honeywell to $141 following a review of the company's annual filing. The 10-K highlights elements of profitability and cash flows, Rubel tells investors in a research note. He expects the non-U.S. business will continue to be more profitable show better growth. Rubel keeps a Buy rating on Honeywell.
12/19/16
OPCO
12/19/16
NO CHANGE
Target $134
OPCO
Outperform
Honeywell price target raised to $134 from $122 at Oppenheimer
Oppenheimer analyst Christopher Glynn raised his price target for Honeywell to $134 from $122, citing its 2017 outlook as he believes quality of drivers are set to improve. He reiterates an Outperform rating on the shares.
03/02/17
OPCO
03/02/17
NO CHANGE
Target $148
OPCO
Outperform
Honeywell price target raised to $148 from $134 at Oppenheimer
Oppenheimer analyst Christopher Glynn raised his price target for Honeywell to $148 from $134 as OM track record exceeds new commitments, organic outlook appears conditioned by recent years' macro headwinds. Further, with defense spending set to turn and Honeywell indicating AM outgrowth of flight hours this year, the analyst thinks an upward tweak of Aero guide could materialize during 2017. He reiterates an Outperform rating on the shares.
12/13/16
UBSW
12/13/16
NO CHANGE
UBSW
Neutral
Earlier than expected Boeing 777 rate cut negative for suppliers, says UBS
UBS analyst David Strauss said that while Boeing (BA) had previously signaled a 777 production rate cut was coming, he thinks the now-announced cut to 5 planes per month in mid-2017 is 3 to 6 months earlier than expected. He sees the earlier than expected transition as having negative implications for key 777 suppliers, including B/E Aerospace (BEAV), GE (GE), Honeywell (HON), Spirit AeroSystems (SPR) and Triumph Group (TGI). Strauss keeps a Neutral rating on Boeing, as he believes 777X development will burn a couple billion per year with overall FCF declining during this period, but also said the company's 30% dividend increase and $14B buyback announcement signals strong confidence in its cash flow outlook.
V Visa

04/19/17
OPCO
04/19/17
NO CHANGE
OPCO
Oppenheimer bullish on Visa, MasterCard ahead of results
Oppenheimer analyst Glenn Greene reiterates Outperform ratings for MasterCard (MA) and Visa (V) and $120 and $95 price targets, respectively, heading into results. The analyst is encouraged by "solid" January intra-quarter volume growth, improving gas price trends, strong retail sales growth, and broadly positive card issuer trends. Further, Greene continues to believe that MasterCard and Visa are attractive at current levels, given their defensible market positions and strong long-term prospects. Nonetheless, he prefers Visa relative to MasterCard at present given the continuing U.S. volume boost from the Costco (COST)/USAA wins and JPMorgan Chase (JPM) Sapphire Reserve momentum, apparent conservative guidance, and Visa Europe accretion benefits.
04/21/17
OPCO
04/21/17
NO CHANGE
Target $100
OPCO
Outperform
Visa price target raised to $100 from $95 at Oppenheimer
Oppenheimer analyst Glenn Greene raised his price target for Visa to $100 from $95 after the company reported strong upside Q2 results. The analyst reiterates an Outperform rating on the shares.
04/21/17
FBCO
04/21/17
NO CHANGE
Target $105
FBCO
Outperform
Visa price target raised to $105 from $100 at Credit Suisse
Credit Suisse analyst Moshe Orenbuch raised his price target for Visa to $105 from $100 following a Q2 beat on higher revenues and lower taxes. The analyst reiterates an Outperform rating on the shares.
04/21/17
BERN
04/21/17
NO CHANGE
BERN
Visa price target raised to $110 from $105 at Bernstein
Bernstein analyst Lisa Ellis says that Visa reported "strong" results, and the analyst expects the stock's positive momentum to continue going forward. She raised her price target on the shares to $110 from $105 and continues to identify the stock as her top pick.
HA Hawaiian Holdings
$53.25

1.35 (2.60%)

04/21/17
04/21/17
UPGRADE

Buy
Hawaiian Holdings upgraded on valuation, fundamental strength at Buckingham
As previously reported, Buckingham upgraded Hawaiian Holdings to Buy from Neutral and raised its price target to $63 from $55. The firm said there is a valuation disconnect as shares are down 9% year-to-date and underlying fundamentals remain strong. Buckingham's analyst has reduced concerns about competitive capacity between Hawaii and Japan due to domestic momentum and international strength elsewhere and raised estimates saying revenue is trending wall above forecasts.
04/21/17
BUCK
04/21/17
UPGRADE
BUCK
Buy
Hawaiian Holdings upgraded to Buy from Neutral at Buckingham
02/09/17
WOLF
02/09/17
UPGRADE
WOLF
Outperform
Hawaiian Holdings upgraded to Outperform from Peer Perform at Wolfe Research
02/09/17
02/09/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Viacom (VIA, VIAB) upgraded to Outperform from Market Perform at Wells Fargo with analyst Marci Ryvicker saying the company's first quarter results prove its turnaround is "real and likely to continue." The strategic plan put in place by CEO Bakish makes sense, Ryvicker tells investors in a research note. The analyst raised his price target range for the shares to $48-$50 from $38-$40. 2. Micron (MU) upgraded to Buy from Underperform at BofA/Merrill. 3. Sanofi (SNY) upgraded to Buy from Neutral at Natixis. 4. Hawaiian Holdings (HA) upgraded to Outperform from Peer Perform at Wolfe Research. 5. Baker Hughes (BHI) upgraded to Positive from Neutral at Susquehanna with analyst Charles Minervino citing the selloff in shares and its upside opportunity associated with a US spending upcycle, synergies from its joint-venture with General Electric (GE), and the growth opportunities that could develop from a partnership with a diversified global oilfield services company. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
COL Rockwell Collins
$104.70

5.11 (5.13%)

03/20/17
03/20/17
UPGRADE
Target $120

Outperform
Rockwell Collins upgraded to Outperform at Credit Suisse
As previously reported, Credit Suisse analyst Robert Spingarn upgraded Rockwell Collins (COL) to Outperform from Neutral as he expects a series of positive catalysts over the next 12 months. The analyst also sees a "strong pro-forma financial profile" with the ability to quickly delever, and says the B/E Aerospace (BEAV) acquisition is not priced in. Spingarn raised his price target on Rockwell Collins' to $120 from $92.
04/19/17
BARD
04/19/17
UPGRADE
Target $118
BARD
Outperform
Rockwell Collins upgraded to Outperform from Neutral at Baird
Baird analyst Peter Arment upgraded Rockwell Collins to Outperform from Neutral to reflect the recently closed acquisition of B/E Aerospace, which he views as having compelling accretion and cash flow generation. Arment believes investors should add or establish positions in Rockwell Collins below $100 per share and he raised his price target to $118 from $90.
04/04/17
UBSW
04/04/17
NO CHANGE
Target $122
UBSW
Buy
Rockwell Collins price target raised to $122 from $108 at UBS
UBS analyst David Strauss raised his price target on Rockwell Collins (COL) to $122 from $108 on expectations the B/E Aerospace (BEAV) acquisition will close over the near-term, leading to higher earnings estimates and free cash flow. Strauss maintained his Buy rating on Rockwell Collins shares.
03/20/17
FBCO
03/20/17
UPGRADE
FBCO
Outperform
Rockwell Collins upgraded to Outperform from Neutral at Credit Suisse
PFPT Proofpoint
$77.65

6.65 (9.37%)

04/21/17
RBCM
04/21/17
NO CHANGE
RBCM
Proofpoint reported 'impressive' Q1 results, says RBC Capital
RBC Capital analyst Matthew Hedberg says that Proofpoint reported "impressive" Q1 results and guidance. The analyst thinks that the company has many growth drivers going forward, and he keeps a $92 price target and an Outperform rating on the shares.
04/20/17
BARD
04/20/17
DOWNGRADE
Target $77
BARD
Neutral
Proofpoint downgraded to Neutral at Baird
As reported previously, Baird analyst Jayson Noland downgraded Proofpoint to Neutral from Outperform citing concerns about sales execution that have accelerated lately. The analyst sees downside risk to earnings, though he said the company is still best-in-class in network security. Noland lowered his price target to $77 from $92 on Proofpoint shares.
04/20/17
BARD
04/20/17
DOWNGRADE
BARD
Neutral
Proofpoint downgraded to Neutral from Outperform at Baird
04/21/17
PIPR
04/21/17
NO CHANGE
Target $90
PIPR
Overweight
Proofpoint remains a top pick for 2017 at Piper Jaffray
Piper Jaffray analyst Andrew Nowinski says Proofpoint remains a top pick for 2017 after reporting "yet another solid quarter." He believes the company has multiple growth drivers that are still in the early innings and that consensus estimates remain conservative. The analyst reiterates an Overweight rating on Proofpoint with a $90 price target.
GS Goldman Sachs
$216.86

-1.2 (-0.55%)

04/20/17
04/20/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Starbucks (SBUX) upgraded to Buy from Hold at Stifel with analyst Mark Astrachan saying he views valuation as attractive and expects multiple expansion from accelerating U.S. comparable store sales growth to at least 5%-6% for the next four quarters starting in the June quarter. The analyst said shares have underperformed consumer and restaurant peers over the past 12 months and expects outperformance to be driven by meeting comp expectations. 2. Goldman Sachs (GS) upgraded to Overweight from Neutral at Atlantic Equities with analyst Christopher Wheeler telling investors investors shares are "oversold." The analyst expects the FICC business to bounce back and made just a small reduction in estimates to account for further cost measures. 3. Lear (LEA) upgraded to Outperform from Neutral at Baird with analyst David Leiker citing its recent underperformance despite improving fundamentals and a strong global auto backdrop. Leiker raised his price target to $161 from $160 on Lear shares. 4. Discovery (DISCA) upgraded to Neutral from Sell at Citi with analyst Jason Bazinet saying he sees little chance of material downward revisions to consensus earnings estimates. The analyst views the risk/reward as more balanced at current levels and upped his price target for the shares to $30 from $27. 5. Gap (GPS) upgraded to Neutral from Underweight at JPMorgan with analyst Matthew Boss citing the underperformance of the shares over the past 18 months and his fieldwork which suggests stability at Old Navy. The analyst raised his price target for the shares to $24 from $21. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/20/17
ATLE
04/20/17
UPGRADE
Target $252
ATLE
Overweight
Goldman Sachs upgraded to Overweight, shares 'oversold,' says Atlantic Equities
Atlantic Equities analyst Christopher Wheeler upgraded Goldman Sachs to Overweight from Neutral and lowered his price target to $252 from $254 telling investors investors shares are "oversold." The analyst expects the FICC business to bounce back and made just a small reduction in estimates to account for further cost measures.
04/19/17
04/19/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Goldman Sachs (GS) upgraded to Neutral from Sell at Citi with analyst Keith Horowitz saying yesterday's post-earnings selloff took out the excess valuation premium. The analyst believes the risk/reward is now more balanced. He keeps a $225 price target for Goldman shares. 2. HP Inc. (HPQ) upgraded to Overweight from Equal Weight at Barclays with analyst Mark Moskowitz saying he expects earnings to return later this year amid improving PC trends and the end of the printing supplies glut. 3. WestRock (WRK) upgraded to Outperform from Sector Perform at RBC Capital and to Buy from Neutral at Goldman Sachs. 4. Coca-Cola (KO) upgraded to Outperform from Neutral at Credit Suisse with analyst Laurent Grandet saying with incoming CEO James Quincey taking over on May 1, and the refranchising nearly complete, Coca-Cola "has all the pieces in place to be successful again." The company has "significant balance sheet flexibility" to invest in the business and fill the gaps in the current portfolio, the analyst adds. 5. Fastenal (FAST) upgraded to Outperform from Neutral at Credit Suisse with analyst Andrew Buscaglia saying the selloff since the first quarter report has created a buying opportunity. The analyst views Fastenal as a best-in-class distributor with significant manufacturing exposure with very high operating leverage in an upcycle. Buscaglia said a recent private distributor survey indicates a majority of respondents expect price increases over the next three months and believe the company may be able to increase prices, which would surprise the Street. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/19/17
ARGS
04/19/17
NO CHANGE
ARGS
Goldman Sachs reported 'solid' Q1 results, says Argus
Argus analyst Stephen Biggar says that Goldman reported "solid" Q1 results, but he says that earnings expectations for the company were "inflated,." Biggar thinks that the company faces difficult comparisons in some of its business lines after reporting strong 2016 results. He keeps a Hold rating on the shares.
BAC Bank of America
$22.71

-0.36 (-1.56%)

04/04/17
04/04/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Alphabet (GOOG, GOOGL) downgraded to Market Perform from Outperform at BMO Capital with analyst Daniel Salmon saying Amazon's (AMZN) ad business represents Google's biggest competitive headwind since Facebook (FB). The analyst believes Google can still grow revenue at 15%-20% over the mid-and long term, but he sees a lower likelihood of topping expectations as Amazon's ad business rises. Salmon continues to prefer Alphabet shares to Facebook, however. He moved Amazon to his top pick this morning and upped his price target for the shares to $1,200. 2. NVIDIA (NVDA) downgraded to Underweight from Sector Weight at Pacific Crest. 3. Nike (NKE) downgraded to Hold from Buy at Argus with analyst John Staszak saying he expects the company's growth to slow over the next 12 months due to competition from Adidas (ADDYY) and Under Armour (UAA). 4. Urban Outfitters (URBN) and L Brands (LB) were downgraded to Neutral from Buy at Citi. 5. Bank of America (BAC) downgraded to Neutral from Buy at Citi with analyst Keith Horowitz saying the stock's outperformance since the U.S. election has substantially closed the valuation gap with JPMorgan (JPM). "We do not see a lot left to play for," Horowitz tells investors in a research note. He lowered his price target for Bank of America shares to $25 from $26. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/19/17
RBCM
04/19/17
NO CHANGE
RBCM
Bank of America reported 'knockout' results, says RBC Capital
RBC Capital analyst Gerard Cassidy says that Bank of America reported "knockout" Q1 results that were better than the other three "Big Four" banks. The analyst says that the company has momentum heading into the rest of the year. He keeps a $26 price target and an Outperform rating on the shares.
JNJ Johnson & Johnson
$121.76

-0.11 (-0.09%)

04/11/17
JPMS
04/11/17
NO CHANGE
Target $125
JPMS
Neutral
JPMorgan remains cautious on United Therapeutics after doctor survey
After surveying 35 physicians who treat pulmonary hypertension, JPMorgan analyst Jessica Fye remains cautious on shares of United Therapeutics (UTHR). The survey showed physicians expect oral prostacyclin use to drive overall prostacyclin category growth but that Johnson & Johnson's (JNJ) Uptravi will remain the preferred oral agent over United Therapeutics' Orenitram. Even with the stock pulling back 27% from the February highs, Fye does not see enough reasons to get more constructive on United Therapeutics. She keeps a Neutral rating on the name with a $125 price target.
04/19/17
LEER
04/19/17
NO CHANGE
Target $140
LEER
Outperform
Johnson & Johnson price target lowered to $140 from $150 at Leerink
Leerink analyst Danielle Antalffy lowered her price target for Johnson & Johnson to $140 from $150 on valuation. The analyst notes that the shares sold off as investors seemed taken aback by weakness in both non-REMICADE Pharma and Consumer, but he points out that there are a number of potential drivers of an improving outlook going forward, including Medical Devices growth reacceleration, continued strong double-digit growth of key new drugs, and likely consumer growth reacceleration as the macroeconomic environment improves and with consumer confidence at its highest level in years. The analyst reiterates an Outperform rating on the shares.
04/19/17
UBSW
04/19/17
NO CHANGE
Target $136
UBSW
Buy
Johnson & Johnson weakness a buying opportunity, says UBS
UBS analyst Matt Miksic believes Johnson & Johnson (JNJ) delivered a solid bottom line beat on in-line sales but prior period adjustments impacted Pharma growth, making the as-reported results look less robust. He raised his estimates to include the Actelion (ALIOF), deal which is expected to close in Q2. Miksic views the initial pullback in the stock as creating a particularly attractive entry point for investors. Miksic reiterated his Buy rating and $136 price target on Johnson & Johnson shares.
04/19/17
RBCM
04/19/17
NO CHANGE
RBCM
Long-term investors should buy Johnson & Johnson on weakness, says RBC Capital
RBC Capital analyst Glenn Novarro notes that Johnson & Johnson's stock is now 10% below its average P/E level of the past five years. The analyst expects the stock to "trade sideways" for the next few months, but he is upbeat about the company's pharma unit heading into 2018. He recommends that long-term investors buy the stock on weakness. He keeps a $128 price target and an Outperform rating on the shares.
NFLX Netflix
$142.87

1.69 (1.20%)

04/18/17
MSCO
04/18/17
NO CHANGE
Target $175
MSCO
Overweight
Netflix price target raised to $175, growth not over, says Morgan Stanley
Morgan Stanley analyst Benjamin Swinburne said Netflix Q1 results show growth is not over and Q2 guidance for higher year-over-year net adds in the mature US market highlights global growth potential. The analyst said the overall business looks increasingly predictable and is expanding its margins nicely as it continues to scale. Swinburne raised Netflix's price target to $175 from $165 and reiterated his Overweight rating on shares.
04/18/17
ADAM
04/18/17
NO CHANGE
Target $165
ADAM
Buy
Netflix release slate keeps Canaccord buyers of the stock
Canaccord analyst Michael Graham noted Netflix reported solid Q1 results and said key releases are being pushed into Q2. Given the company's success with original programming, he remains a buyer of the shares. Graham also said the company's increase in local languages should help drive subscriber additions. Graham maintained his Buy rating and raised his price target to $165 from $160 on Netflix shares.
04/18/17
FBCO
04/18/17
NO CHANGE
Target $149
FBCO
Neutral
Netflix price target raised to $149 from $144 at Credit Suisse
Credit Suisse analyst Stephen Ju raised his price target for Netflix to $149 from $144 after Q1 results, as he anticipates a "sharper increase" in free cash flow dollars over the medium to longer term. The analyst reiterates a Neutral rating on the shares, citing balanced risk/reward.
CUDA Barracuda
$20.14

0.66 (3.39%)

04/18/17
BARD
04/18/17
NO CHANGE
Target $31
BARD
Outperform
Barracuda remains a best idea for 2017, says Baird
Baird analyst Jayson Noland said Q4 results for Barracuda were solid, although its guidance was a little light, which he believes is a function of the shift to a cloud-based business model. He expects the company's transition to a cloud-based model to be faster than most other companies and said it remains one of his best ideas for 2017. Noland reiterated his Outperform rating and $31 price target on Barracuda shares.
04/18/17
IMPC
04/18/17
UPGRADE
IMPC
In-Line
Barracuda upgraded to In-Line from Underperform at Imperial Capital
04/13/17
JMPS
04/13/17
NO CHANGE
JMPS
Barracuda Q4 results should beat expectations, says JMP Securities
JMP Securities analyst Erik Suppiger predicts that Barracuda's Q4 results will beat expectations. He thinks that the company's Q1 guidance will come in slightly above expectations. However, the analyst keeps a Market Perform rating on the name, citing valuation.
04/18/17
04/18/17
UPGRADE
Target $20

In-Line
Barracuda upgraded to In-Line after earnings at Imperial Capital
As previously reported, Imperial Capital analyst Michael Kim upgraded Barracuda Networks to In-Line from Underperform after the company's Q4 earnings topped his estimates and the consensus view. Though the pullback in the stock prompts him to raise his rating, Kim lowered his price target on Barracuda shares to $20 from $21 as he expects greater headwinds from the company's legacy on-premise business.
IBM IBM
$160.38

-1.92 (-1.18%)

04/19/17
SOCG
04/19/17
DOWNGRADE
SOCG
Sell
IBM downgraded to Sell from Hold at Societe Generale
04/20/17
ARGS
04/20/17
NO CHANGE
ARGS
IBM a value play that's 'becoming a growth story,' says Argus
After IBM reported lower than expected revenue and what Argus analyst Jim Kelleher sees as "weak" gross margins, the analyst says that the stock remains a value play, given its decline from its peak prices above $215. However, the analyst thinks that the company is on the path to becoming a unique cloud and cognitive paltform" and is transitioning to "a growth story." The analyst is upbeat on the company's Watson solution and keeps a $192 price target and a Buy rating on the stock.
04/19/17
BOFA
04/19/17
NO CHANGE
Target $200
BOFA
Buy
IBM pullback a buying opportunity, says BofA/Merrill
BofA/Merrill analyst Wamsi Mohan said IBM's full year guidance remains unchanged and achievable driven by the new Mainframe cycle ramp, lower dilution from prior M&A, completion of deal previously pushed out, and improving trends in GBS. The analyst said the 3.5% dividend yield limits incremental downside and views the weakness as a buying opportunity. Mohan has a Buy rating and a $200 price target on shares.
04/19/17
JEFF
04/19/17
NO CHANGE
Target $135
JEFF
Underperform
IBM price target lowered to $135 from $145 at Jefferies
Jefferies analyst James Kisner lowered his price target for IBM shares to $135 saying last night's earnings results were "poor quality" given the large contribution from intellectual property income and an artificially low tax rate. The analyst views the quarter as supporting his view that IBM's recently poor earning quality "masks ongoing secular headwinds that will likely result in disappointment for investors." He reiterates an Underperform rating on IBM. The stock in premarket trading is down 5% to $161.12.
IBKR Interactive Brokers
$34.03

-0.3 (-0.87%)

04/19/17
KBWI
04/19/17
DOWNGRADE
Target $38
KBWI
Market Perform
Interactive Brokers downgraded to Market Perform at Keefe Bruyette
Keefe Bruyette analyst Kyle Voigt downgraded Interactive Brokers to Market Perform from Outperform and lowered his price target for the shares to $38 from $41. The analyst cut his estimates following the company's Q1 results.
04/19/17
04/19/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Ultragenyx (RARE) was downgraded to Neutral from Buy at H.C. Wainwright and to Neutral from Outperform at Wedbush. 2. Grainger (GWW) downgraded to Underperform on pricing risks at Credit Suisse with analyst Andrew Buscaglia telling investors he sees more uncertainty around its pricing strategy for its highest margin mid-sized customers and continued gross margin declines in 2018 that will weigh on shares. Buscaglia believes Grainger is the most susceptible to the Amazon (AMZN) threat as evidenced by its pricing actions to its more profitable smaller-medium sized customers and said its move online makes it more susceptible to competitive pricing. 3. Interactive Brokers (IBKR) downgraded to Market Perform at Keefe Bruyette with analyst Kyle Voigt citing the company's first quarter results. 4. Regions Financial (RF) downgraded to In Line from Outperform at Evercore ISI with analyst John Pancari citing limit upside to valuation given mounting earnings headwinds. 5. Sirius XM (SIRI) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Benjamin Swinburne telling investors the business is maturing and growth is slowing. Swinburne said Sirius is executing well, but the benefit from new car turnover has likely peaked and not longer adds material to the subscription base, and adds used car growth has also peaked. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/10/17
GSCO
01/10/17
UPGRADE
Target $40
GSCO
Neutral
Interactive Brokers upgraded to Neutral from Sell at Goldman
Goldman analyst Conor Fitzgerald upgraded Interactive Brokers to Neutral and raised its price target to $40 from $39 citing inline valuation with peers.
04/03/17
WELS
04/03/17
DOWNGRADE
WELS
Underperform
Interactive Brokers downgraded to Underperform Perform at Wells Fargo
Wells Fargo analyst Christopher Harris downgraded Interactive Brokers to Underperform from Market Perform saying the company is likely to face near-term challenges with the wind-down of its Market Making operation and commissions growth. The analyst expects the stock "to struggle during this transition period." He lowered his price target range for Interactive shares to $30-$34 from $35-$39.
TRV Travelers
$119.10

0.22 (0.19%)

02/13/17
FBRC
02/13/17
DOWNGRADE
Target $119
FBRC
Market Perform
Travelers downgraded to Market Perform from Outperform at FBR Capital
FBR Capital analyst Randy Binner downgraded Travelers to Market Perform citing valuation and pricing challenges in the auto segment and broader commercial lines. The analyst has a $119 price target for the shares.
01/26/17
JPMS
01/26/17
NO CHANGE
Target $120
JPMS
Neutral
JPMorgan incrementally cautious after Travelers meeting
JPMorgan analyst Sarah DeWitt says she's incrementally cautious on shares of Travelers after meeting with the company's management. The analyst says she didn't receive "significant comfort" that auto insurance losses won't deteriorate further while higher U.S. inflation could mean reserve releases slow. The analyst adds that management "appeared slightly less inclined" to pursue acquisitions. DeWitt keeps a Neutral rating on Travelers with a $120 price target.
01/10/17
GSCO
01/10/17
DOWNGRADE
Target $107
GSCO
Sell
Travelers downgraded to Sell from Neutral at Goldman
Goldman analyst Michael Nannizzi downgraded Travelers to Sell and lowered its price target to $107 from $116. The analyst said shares are up 10% since the election and sees fewer catalysts ahead given its large muni portfolio and lack of rate action to date.
01/17/17
MACQ
01/17/17
UPGRADE
MACQ
Outperform
Travelers upgraded to Outperform from Underperform at Macquarie
Macquarie analyst Amit Kumar upgraded Travelers two notches to Outperform from Underperform with a $134 price target. The analyst expects Travelers to significantly benefit from the improving US business environment due to Trump's focus on business and a lower corporate tax rate.
EBAY eBay
$32.18

-0.35 (-1.08%)

04/20/17
04/20/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Amazon.com (AMZN) downgraded to Peer Perform from Outperform at Wolfe Research with analyst Scott Mushkin saying shares are approaching his price target and he expects increasing competition through year-end. 2. Time Warner (TWX) downgraded to Hold from Buy at Pivotal Research with analyst Brian Wieser saying shares are trading near the value of AT&T's (T) offering price. 3. Molson Coors (TAP) downgraded to Market Perform from Outperform at Cowen with analyst Vivien Azer citing expectations for persistent beer volume headwinds. The analyst believes alcohol consumption could be pressured for at least the next decade, partly due to increased cannabis use, and a contraction in the alcohol cycle. Azer said Molson is uniquely exposed to the increasingly vibrant and growing cannabis markets and notes there is an inverse relationship between cannabis use and alcohol consumption over time. 4. eBay (EBAY) downgraded to Neutral from Buy at Monness Crespi with analyst James Cakmak saying he sees insufficient upside to estimates to justify the lofty valuation. The analyst said the path to double-digit growth may be pushed out 2019 and limited potential to outperform topline expectations in 2017. Further, the analyst sees margin pressures from product mix towards StubHub and rising development spend for the backend, and limited opportunities for multiple expansion. 5. Ruth's Hospitality (RUTH) downgraded to Market Perform from Outperform at Raymond James with analyst Brian Vaccaro citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/20/17
JMPS
04/20/17
NO CHANGE
JMPS
eBay outlook has improved, says JMP Securities
After eBay reported in-line Q1 results and lower than expected Q2 guidance, JMP Securities analyst Ronald Josey says he is nonetheless more upbeat about the company's growth outlook. The analyst says that the company has improved its user experience, while its structured data rollout could enable its GMV growth to accelerate in 2H17. The analyst keeps a Market Perform rating on the stock, citing valuation.
04/20/17
MONN
04/20/17
DOWNGRADE
Target $17.5
MONN
Neutral
eBay downgraded to Neutral from Buy at Monness Crespi
Monness Crespi analyst James Cakmak downgraded eBay to Neutral saying he sees insufficient upside to estimates to justify the lofty valuation. The analyst said the path to double-digit growth may be pushed out 2019 and limited potential to outperform topline expectations in 2017. Further, the analyst sees margin pressures from product mix towards StubHub and rising development spend for the backend, and limited opportunities for multiple expansion.
04/20/17
HDLY
04/20/17
DOWNGRADE
Target $38.5
HDLY
Long-Term Buy
eBay downgraded to Long-Term Buy from Buy at Hilliard Lyons
Hilliard Lyons analyst Stephen Turner downgraded eBay to Long-Term Buy from Buy, stating that the company's Q1 results were slightly ahead of his view while its Q2 guidance missed his forecast. However, he raised his price target on the shares to $38.50 from $36.
PM Philip Morris
$109.62

-0.36 (-0.33%)

02/17/17
WELS
02/17/17
NO CHANGE
WELS
Philip Morris likely to raise iQOS guidance, says Wells Fargo
Wells Fargo expects Philip Morris (PM) to announce on February 22 that it will file an FDA application to commercialize its iQOS smokeless cigarettes in the U.S. The firm predicts that the company will also raise its 2020 iQOS incremental profit target by $0.3B to $1.0-$1.5B. Wells sees a 70% chance of Philip Morris acquiring Altria Group (MO), and it says that such a deal could enable iQOs to obtain an additional $10B in operating income from iQOS by 2025. Wells keeps Outperform ratings on Philip Morris and Altria.
04/21/17
WELS
04/21/17
NO CHANGE
WELS
Philip Morris shares should be bought on weakness, says Wells Fargo
Wells Fargo says that Philip Morris' lower than expected EPS and volumes were caused by its decision to exit low margin markets. The firm says that the results support the company's strategy of boosting its profitability over the longer term ,and Wells Fargo recommends buying the stock on weakness.
01/18/17
SBSH
01/18/17
DOWNGRADE
Target $60
SBSH
Neutral
Reynolds American downgraded to Neutral from Buy at Citi
Citi analyst Adam Spielman downgraded Reynolds American (RAI) to Neutral from Buy citing its deal to be acquired fully by British American Tobacco (BTI). He adds that he sees the proposed deal putting further pressure on Altria (MO) and Philip Morris (PM) to recombine.
02/08/17
SBSH
02/08/17
NO CHANGE
SBSH
Citi says 'fairly unlikely' Philip Morris buys Altria Group
It is "fairly unlikely," although not impossible, that Philip Morris (PM) acquires Altria Group (MO), Citi analyst Adam Spielman tells investors in a research note. The analyst points out that according to Bloomberg, there is greater speculation that Altria Group will be bid for than for any other major company. Spielman does not believe Philip Morris buying Altria would generate adequate financial returns. He notes the takeover speculation is triggered by British American Tobacco's (BAT) decision to buy Reynolds American (RAI), the number two player in U.S. tobacco.
GE General Electric
$29.55

-0.72 (-2.38%)

03/31/17
WBLR
03/31/17
NO CHANGE
WBLR
Outperform
General Electric shares set to move higher, says William Blair
William Blair analyst Nicholas Heymann believes shares of General Electric are set to move higher, not on management changes, but stronger fundamentals as the "external macro environment continues to improve." If GE achieves its more aggressive 2017 fundamental performance hurdles, the shares should be set to move steadily higher to the mid- to upper $30s, Heymann tells investors in a research note. The analyst sees potential upside to estimates from U.S. corporate tax reform and U.S. privately financed infrastructure modernization. He keeps an Outperform rating on GE shares.
03/13/17
JPMS
03/13/17
NO CHANGE
Target $29
JPMS
Underweight
JPMorgan says use GE rally as selling opportunity
JPMorgan analyst C. Stephen Tusa recommends using Friday's rally in General Electric shares as a selling opportunity. A possible CEO change does not change the analyst's view that GE is an expensive stock. Discussion of an activist, who owns less than 1% of the company, trying to make changes is a re-run of the case made two years ago, Tusa tells investors in a research note. The analyst does not see much a GE activist can do. The company's "stubbornly low growth and secular challenges embedded in end markets" can't be fixed by a CEO, the analyst contends. Tusa keeps an Underweight rating on shares of GE with a $29 price target. The stock rallied Friday to $30.28 after Fox Business reported that CEO Jeff Immelt is on the "hot seat" with activist Nelson Peltz.
04/10/17
FBRC
04/10/17
NO CHANGE
FBRC
FBR views Tesco as most likely takeover in Oilfield Services
FBR Capital analyst Thomas Curran says that within his Oilfield Services coverage, Tesco (TESO) has the highest probability of a straight acquisition. In GE Oil & Gas (GE) and Forum Energy (FET), Tesco has at least two potential strategic acquirers with "highly compelling logic," Curran tells investors in a research note. He believes a buyer could offer $10 per share. Tesco closed Friday at $7.30.
03/28/17
JPMS
03/28/17
NO CHANGE
Target $27
JPMS
Underweight
General Electric price target lowered to $27 from $29 at JPMorgan
JPMorgan analyst C. Stephen Tusa lowered his price target for General Electric to $27 and keeps an Underweight rating on the shares. The sell-side bull thesis is shifting focus away from the $2.00 earnings per share target in 2018 to free cash flow, which is "seemingly appropriately," Tusa tells investors in a research note. The analyst views the emerging bull case on free cash flow as "overstated and not plausible." He notes his new $27 price target still implies a premium 4% free cash yield and "solid" 3.5% dividend yield.
MAT Mattel
$21.79

-3.42 (-13.57%)

02/13/17
GSCO
02/13/17
INITIATION
Target $27
GSCO
Neutral
Mattel initiated with a Neutral at Goldman
Goldman analyst Michael Ng initiated Mattel with a Neutral and a $27 price target. The analyst said Mattel is undergoing a turnaround in several of its core brands but consensus estimates are already looking for a meaningful recovery, creating increased risk.
02/08/17
PIPR
02/08/17
NO CHANGE
PIPR
Piper discusses resurfacing of Hasbro, Mattel deal speculation
Piper Jaffray analyst Stephanie Wissink points out that over her firm's 15 years of coverage, speculation of a merger between Hasbro (HAS) and Mattel (MAT) has surfaced several times. Hasbro's strong Q4 earnings report and share rally, in contrast with Mattel's negative Q4 preannouncement and pullback, has reignited the conjecture, Wissink tells investors in a research note. Economically a merger would create value, but a combination of the number two and three toy companies "would require significant evaluation from anti-trust authorities," the analyst writes. She believes a deal is possible if the Federal Trade Commission widens the boundaries around "youth entertainment & play," say to include video games, digital games and media. Hasbro closed yesterday up 67c to $94.98 while Mattel, after rallying in early trading, closed down 4c to $25.88. Wissink adds that she can find upwards of $500M of merger synergies if the two companies were to combine.
03/14/17
UBSW
03/14/17
NO CHANGE
UBSW
Buy
UBS discusses scenarios for hypothetical Mattel/Hasbro merger
UBS analyst Arpine Kocharyan noted market speculation about a potential merger of Hasbro (HAS) and Mattel (MAT). While admitting she has no view on the possibility of a deal happening, she does say there is large equity valuation gap between the two, with Mattel pricing in a potential dividend cut, and expressed her view that industry consolidation could pick up in 2017. Koocharyan maintains her Buy rating on Mattel and Neutral rating on Hasbro shares.
02/13/17
02/13/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Air Products (APD) reinstated with an Overweight at Barclays. 2. Hasbro (HAS) was initiated with a Buy at Goldman, while Mattel (MAT) was initiated with a Neutral. 3. Jagged Peak Energy (JAG) initiated with a Positive at Susquehanna. 4. Kimbell Royalty Partners (KRP) initiated with a Buy at Wunderlich. 5. HollyFrontier (HFC) reinstated with a Sell at Goldman. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
INCY Incyte
$123.01

-0.1 (-0.08%)

04/19/17
FBCO
04/19/17
NO CHANGE
Target $167
FBCO
Outperform
Incyte price target lowered to $167 from $174 at Credit Suisse
Credit Suisse analyst Alethia Young lowered her price target for Incyte to $167 from $174 on Baricitinib's surprise CRL. The analyst moved baricitinib's U.S. launch to 2019 and lowered the probability of success on U.S. revenues to 80%. Young reiterates an Outperform rating on the shares.
04/18/17
FBCO
04/18/17
INITIATION
Target $174
FBCO
Outperform
Incyte assumed with an Outperform at Credit Suisse
Target $174.

TODAY'S FREE FLY STORIES

ABBV

AbbVie

$63.82

0.04 (0.06%)

, ALXN

Alexion

$116.82

-1.9 (-1.60%)

04:55
04/23/17
04/23
04:55
04/23/17
04:55
Conference/Events
European Association for the Study of Liver »

International Liver…

ABBV

AbbVie

$63.82

0.04 (0.06%)

ALXN

Alexion

$116.82

-1.9 (-1.60%)

BAX

Baxter

$52.88

-0.01 (-0.02%)

CPHD

Cepheid

GALT

Galectin Therapeutics

$3.09

-0.14 (-4.33%)

GILD

Gilead

$65.93

-0.57 (-0.86%)

ICPT

Intercept

$107.89

0.7 (0.65%)

JWA

John Wiley & Sons; also tag JWB

NVS

Novartis

$73.40

-0.22 (-0.30%)

OSUR

OraSure

$12.67

0.03 (0.24%)

SIEGY

Siemens

$67.34

-0.197 (-0.29%)

VTL

Vital Therapies

$3.50

-0.1 (-2.78%)

ARWR

Arrowhead

$1.52

0.01 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 02

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 16

    May

  • 06

    Jun

  • 26

    Jun

  • 23

    Oct

AAPL

Apple

$142.27

-0.17 (-0.12%)

, FB

Facebook

$143.68

-0.12 (-0.08%)

13:57
04/22/17
04/22
13:57
04/22/17
13:57
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$142.27

-0.17 (-0.12%)

FB

Facebook

$143.68

-0.12 (-0.08%)

GOOG

Alphabet

$843.19

1.54 (0.18%)

GOOGL

Alphabet Class A

$858.95

-1.13 (-0.13%)

AMZN

Amazon.com

$898.53

-3.53 (-0.39%)

MSFT

Microsoft

$66.40

0.9 (1.37%)

STLD

Steel Dynamics

$35.37

0.46 (1.32%)

AKS

AK Steel

$6.72

-0.1 (-1.47%)

X

U.S. Steel

$30.42

-0.09 (-0.29%)

NUE

Nucor

$60.00

-0.35 (-0.58%)

CYH

Community Health

$8.24

-0.11 (-1.32%)

HCA

HCA Holdings

$83.55

-0.57 (-0.68%)

LPNT

LifePoint

$60.85

-0.7 (-1.14%)

THC

Tenet

$15.35

0.36 (2.40%)

UHS

Universal Health

$118.84

-0.29 (-0.24%)

HUM

Humana

$213.67

-0.57 (-0.27%)

BAC

Bank of America

$22.71

-0.36 (-1.56%)

C

Citi

$57.72

-0.69 (-1.18%)

GS

Goldman Sachs

$216.86

-1.2 (-0.55%)

JPM

JPMorgan

$84.52

-1.03 (-1.20%)

MS

Morgan Stanley

$41.80

-0.7 (-1.65%)

USB

U.S. Bancorp

$50.51

-0.17 (-0.34%)

WFC

Wells Fargo

$53.00

-0.5 (-0.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 28

    Apr

  • 02

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 03

    May

  • 09

    May

  • 09

    May

  • 11

    May

  • 16

    May

  • 16

    May

  • 19

    May

  • 22

    May

  • 22

    May

  • 23

    May

  • 25

    May

  • 06

    Jun

  • 06

    Jun

  • 13

    Jun

  • 13

    Jul

  • 14

    Jul

  • 18

    Jul

  • 19

    Jul

  • 25

    Jul

  • 12

    Oct

  • 12

    Oct

  • 17

    Oct

  • 18

    Oct

  • 15

    Jan

  • 17

    Jan

  • 13

    Apr

  • 13

    Jul

  • 12

    Oct

JNS

Janus Capital

$13.15

-0.07 (-0.53%)

13:27
04/22/17
04/22
13:27
04/22/17
13:27
Conference/Events
Janus Capital to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

ABT

Abbott

$43.53

-0.45 (-1.02%)

, ABBV

AbbVie

$63.82

0.04 (0.06%)

04:55
04/22/17
04/22
04:55
04/22/17
04:55
Conference/Events
National Kidney Foundation to hold clinical meeting »

NKF 2017 Spring Clinical…

ABT

Abbott

$43.53

-0.45 (-1.02%)

ABBV

AbbVie

$63.82

0.04 (0.06%)

ALXN

Alexion

$116.82

-1.9 (-1.60%)

AMGN

Amgen

$160.41

-1.63 (-1.01%)

BAX

Baxter

$52.88

-0.01 (-0.02%)

GSK

GlaxoSmithKline

$40.78

0.07 (0.17%)

HZNP

Horizon Pharma

$14.99

-0.25 (-1.64%)

MNK

Mallinckrodt

$43.52

-1.41 (-3.14%)

MRK

Merck

$61.89

-0.66 (-1.06%)

AUPH

Aurinia Pharmaceuticals

$7.11

0.11 (1.57%)

NXTM

NxStage Medical

$27.90

-0.19 (-0.68%)

PLX

Protalix

$1.02

0.02 (2.00%)

RTRX

Retrophin

$18.47

-0.37 (-1.96%)

SNY

Sanofi

$44.09

-0.7 (-1.56%)

SHPG

Shire

$171.94

0.08 (0.05%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$24.29

0.215 (0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 28

    Apr

  • 02

    May

  • 02

    May

  • 03

    May

  • 04

    May

  • 07

    May

  • 08

    May

  • 08

    May

  • 09

    May

  • 10

    May

  • 27

    May

  • 06

    Jun

  • 09

    Jun

  • 14

    Jun

  • 26

    Jun

  • 19

    Jul

  • 14

    Aug

  • 23

    Oct

ABBV

AbbVie

$63.82

0.04 (0.06%)

, ALXN

Alexion

$116.82

-1.9 (-1.60%)

04:55
04/22/17
04/22
04:55
04/22/17
04:55
Conference/Events
European Association for the Study of Liver »

International Liver…

ABBV

AbbVie

$63.82

0.04 (0.06%)

ALXN

Alexion

$116.82

-1.9 (-1.60%)

BAX

Baxter

$52.88

-0.01 (-0.02%)

CPHD

Cepheid

GALT

Galectin Therapeutics

$3.09

-0.14 (-4.33%)

GILD

Gilead

$65.93

-0.57 (-0.86%)

ICPT

Intercept

$107.89

0.7 (0.65%)

JWA

John Wiley & Sons; also tag JWB

NVS

Novartis

$73.40

-0.22 (-0.30%)

OSUR

OraSure

$12.67

0.03 (0.24%)

SIEGY

Siemens

$67.34

-0.197 (-0.29%)

VTL

Vital Therapies

$3.50

-0.1 (-2.78%)

ARWR

Arrowhead

$1.52

0.01 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 22

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 02

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 16

    May

  • 06

    Jun

  • 26

    Jun

  • 23

    Oct

RGEN

Repligen

$35.06

-0.78 (-2.18%)

19:19
04/21/17
04/21
19:19
04/21/17
19:19
Initiation
Repligen initiated at First Analysis »

Repligen initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 30

    May

  • 06

    Jun

TWTR

Twitter

$14.63

-0.02 (-0.14%)

18:07
04/21/17
04/21
18:07
04/21/17
18:07
Periodicals
Homeland Security investigates potential abuse in Twitter case, Reuters says »

The U.S. Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$843.19

1.54 (0.18%)

, GOOGL

Alphabet Class A

$858.95

-1.13 (-0.13%)

17:46
04/21/17
04/21
17:46
04/21/17
17:46
Periodicals
Waymo:Uber misled court on Levandowski using LIDAR secrets, Bloomberg says »

According to Bloomberg,…

GOOG

Alphabet

$843.19

1.54 (0.18%)

GOOGL

Alphabet Class A

$858.95

-1.13 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 22

    May

CDNA

CareDx

$1.00

0.05 (5.26%)

17:33
04/21/17
04/21
17:33
04/21/17
17:33
Hot Stocks
CareDx receives expected letter from Nasdaq »

CareDx announced that, as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBX

Greenbrier

$44.45

-0.2 (-0.45%)

17:33
04/21/17
04/21
17:33
04/21/17
17:33
Hot Stocks
Greenbrier CEO intends to sell one-half of his position in company stock »

The CEO of The Greenbrier…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

CDNA

CareDx

$1.00

0.05 (5.26%)

17:32
04/21/17
04/21
17:32
04/21/17
17:32
Earnings
CareDx backs FY17 revenue view $45M-$50M, consensus $47.62M »

Revenue view excludes any…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDNA

CareDx

$1.00

0.05 (5.26%)

17:32
04/21/17
04/21
17:32
04/21/17
17:32
Earnings
CareDx reports Q4 adjusted EPS (13c), consensus (18c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMMA

Alliance MMA

$1.69

-0.05 (-2.87%)

17:32
04/21/17
04/21
17:32
04/21/17
17:32
Hot Stocks
Alliance MMA announces shareholder filed lawsuit against the company »

Alliance MMA announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDNA

CareDx

$1.00

0.05 (5.26%)

17:30
04/21/17
04/21
17:30
04/21/17
17:30
Hot Stocks
CareDx names Michael Bell CFO »

CareDx announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVO

Novo Nordisk

$35.88

-0.52 (-1.43%)

, XOMA

XOMA

$7.73

0.26 (3.48%)

17:22
04/21/17
04/21
17:22
04/21/17
17:22
Hot Stocks
Novo Nordisk terminates exclusive license agreement with XOMA »

On April 20, XOMA (XOMA)…

NVO

Novo Nordisk

$35.88

-0.52 (-1.43%)

XOMA

XOMA

$7.73

0.26 (3.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 07

    May

  • 18

    May

  • 06

    Jun

HH

Hooper Holmes

$0.72

-0.1973 (-21.44%)

17:21
04/21/17
04/21
17:21
04/21/17
17:21
Hot Stocks
Breaking Hot Stocks news story on Hooper Holmes »

John Pappajohn reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBMS

First Bancshares

$28.00

0.15 (0.54%)

17:14
04/21/17
04/21
17:14
04/21/17
17:14
Earnings
First Bancshares reports Q1 EPS 12 c with items, consensus 35c »

Reports Q1 provision for …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRWI

DragonWave

$1.23

-0.025 (-2.00%)

17:04
04/21/17
04/21
17:04
04/21/17
17:04
Hot Stocks
DragonWave did not regain compliance with Nasdaq listing standards »

DragonWave announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLD

Sears

$13.39

-0.25 (-1.83%)

17:02
04/21/17
04/21
17:02
04/21/17
17:02
Hot Stocks
Sears establishes special committee to market certain real estate properties »

Sears Holdings said its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

SHLD

Sears

$13.39

-0.25 (-1.83%)

17:00
04/21/17
04/21
17:00
04/21/17
17:00
Hot Stocks
Sears names Rob Riecker CFO »

Sears announced that Rob…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

UAL

United Continental

$69.56

-0.24 (-0.34%)

17:00
04/21/17
04/21
17:00
04/21/17
17:00
Hot Stocks
UAL: employee incentive opportunity to be tied to 'customer experience' »

United Continental said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLD

Sears

$13.39

-0.25 (-1.83%)

17:00
04/21/17
04/21
17:00
04/21/17
17:00
Earnings
Sears sees FY17 net income $185M-$285M »

"The retail…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

SHLD

Sears

$13.39

-0.25 (-1.83%)

16:59
04/21/17
04/21
16:59
04/21/17
16:59
Hot Stocks
Sears raises annualized cost savings target to $1.25B from $1B »

Sears Holdings provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

LTBR

Lightbridge

$1.25

-0.06 (-4.58%)

16:51
04/21/17
04/21
16:51
04/21/17
16:51
Hot Stocks
CEO of Lightbridge Seth Grae reports 5.1% stake in company »

As of March 22, Seth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IONS

Ionis Pharmaceuticals

$44.26

1.35 (3.15%)

16:46
04/21/17
04/21
16:46
04/21/17
16:46
Syndicate
Breaking Syndicate news story on Ionis Pharmaceuticals »

Ionis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.